On July 30, INSILICO fell 5.52% in regular trading, trading at HK$40.94/share, with turnover of HK$218 million.
Within the Life Sciences Tools & Services sector where INSILICO belongs, the overall sector experienced broad weakness. Among individual stocks, WUXI BIO down 6.04%, GENSCRIPT BIO down 4.94%, WUXI APPTEC down 4.29%, XTALPI down 3.68%, WUXI XDC down 6.57%.
INSILICO is a company principally engaged in AI-driven drug discovery and pipeline development. The company generates clinical or IND-stage assets through its proprietary AI platform Pharma.AI, and is also involved in software solutions and R&D services related to non-pharmaceutical fields.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments